GLP-1 medications like Ozempic, Wegovy, and Tirzepatide are becoming increasingly popular for rapid weight loss - but are they the right solution for active women who care about body composition, strength, and long-term sustainability?
In this episode, we break down what these medications actually do, who they’re designed for, and the potential risks that often get overlooked - especially for women 35+ navigating fat loss, performance, and hormone changes.
This is not about fear or judgment- it’s about understanding the full picture so you can make informed decisions about your body.
What You’ll Learn in This Episode
Why GLP-1 medications are so appealing for fat loss
What these drugs actually do in the body (and what they don’t do)
Who truly benefits most from GLP-1 medications
The difference between adherence vs dependence
The risk of muscle loss during rapid weight loss
How under-eating can negatively impact performance and recovery
Why many women experience rebound weight gain after stopping
The return of hunger and food noise post-medication
The difference between correlation vs causation in hormone and inflammation improvements
Why appetite suppression doesn’t replace the need for nutrition and behavior skills
The long-term sustainability and financial considerations of GLP-1 use
When these medications can be helpful (when used appropriately)
Key Takeaways
GLP-1 medications do not directly burn fat—they reduce appetite, making it easier to maintain a calorie deficit
Without intentional strength training and adequate protein intake, muscle loss is a real risk
Many of the “benefits” people report (better hormones, less inflammation, more energy) are largely due to weight loss itself—not the drug
If no sustainable habits are built, coming off these medications often leads to rebound weight gain and return of food noise
Long-term success comes from building skills—not relying on appetite suppression
Who These Medications May Be Appropriate For
Individuals with Type 2 diabetes
Those with obesity and significant metabolic dysfunction
Individuals struggling with severe food noise or binge eating patterns
For others—especially active women focused on body composition—there may be more sustainable and effective long-term approaches.
References & Research
Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine.
Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.
Weinheimer EM, Sands LP, Campbell WW. (2010). A systematic review of the effects of weight loss on lean body mass in older adults.
Murphy CH, et al. (2014). Higher protein intake preserves lean mass during weight loss in older adults.
Hall KD, et al. (2016). Persistent metabolic adaptation following weight loss and implications for weight regain.
31 m